RORγt+ B cells express proinflammatory cytokines and promote allo- and auto- immunity

This study identifies a subset of TIM-4-expressing B cells that, through IL-23R signaling and RORγt expression, produce proinflammatory cytokines like IL-17A to drive autoimmunity and allograft rejection while simultaneously inhibiting their own conversion into regulatory B cells.

The Gist

Imagine your immune system as a highly organized security force protecting a fortress (your body). For a long time, scientists thought this force had two main types of guards: the Peacekeepers (Regulatory B cells) who calm things down and stop fights, and the Soldiers (Effector B cells) who attack invaders.

However, this new research discovers a specific, elite squad of Soldiers that has been hiding in plain sight. These are the TIM-4+ B cells, and they are the "hot-headed" troublemakers of the immune system.

Here is the story of what this paper found, broken down with simple analogies:

1. The Two Types of Guards

• The Peacekeepers (TIM-1+ B cells): These are the diplomats. They carry a "Stop" sign and release a calming chemical called IL-10. Their job is to tell the immune system, "Relax, we don't need to fight this," preventing autoimmune diseases (where the body attacks itself) and helping organ transplants survive.
• The Soldiers (TIM-4+ B cells): These are the new stars of the show. The researchers found that these cells are the opposite of the Peacekeepers. Instead of calming things down, they are constantly shouting, "Attack!"

2. The "Th17" Connection

The most exciting discovery is that these TIM-4+ Soldiers don't just shout randomly; they have a very specific, aggressive playbook. They express a master switch gene called RORγt.

Think of RORγt as a "General's Uniform."

• In T-cells (another type of immune cell), wearing this uniform turns them into Th17 cells, which are famous for being very aggressive and causing inflammation.
• This paper found that B cells can wear this same uniform too! When a B cell puts on the RORγt "uniform," it transforms into a TIM-4+ Soldier.

Once transformed, these cells start pumping out a cocktail of inflammatory chemicals (cytokines) like IL-17A, IL-22, and GM-CSF. It's like they are throwing gasoline on a fire.

3. The "Self-Perpetuating Fire" (The Autocrine Loop)

Here is the clever (and dangerous) trick these cells play on themselves:

• The TIM-4+ Soldiers release IL-17A (the gasoline).
• This IL-17A doesn't just attack the enemy; it also hits the Soldier's own "ears."
• Hearing its own shout, the Soldier thinks, "Wow, I must be right! Keep shouting louder!"
• This creates a feedback loop: The more IL-17A they make, the more they make. It locks them into "Attack Mode" and prevents them from ever becoming Peacekeepers.

4. The "Switch" That Won't Flip

Normally, immune cells can change their minds. A Soldier might decide to become a Peacekeeper if the situation calls for it.

• The Problem: Because of the IL-17A feedback loop, the TIM-4+ Soldiers are stuck. They literally cannot turn off their aggression.
• The Evidence: When the researchers genetically removed the ability of these cells to make IL-17A (or the RORγt switch), something amazing happened. The "Soldiers" suddenly stopped shouting. They calmed down, stopped releasing inflammatory chemicals, and actually started releasing the calming IL-10 chemical. They effectively turned into Peacekeepers!

5. What This Means for Disease

The researchers tested this in mice with two major problems:

1. Autoimmunity (EAE): A model for Multiple Sclerosis.
2. Transplant Rejection: When a mouse tries to reject a new organ.

The Result:

• Mice with normal TIM-4+ Soldiers got very sick and rejected their organs quickly.
• Mice where the TIM-4+ Soldiers couldn't make IL-17A (or RORγt) had much milder disease and their organ transplants survived much longer.

The Big Picture Analogy

Imagine a neighborhood where a few neighbors (TIM-4+ B cells) are constantly yelling "Fire!" and throwing matches.

• Because they are yelling so loud, they convince themselves the fire is real and keep throwing more matches (the IL-17A loop).
• They also prevent the other neighbors (the Peacekeepers) from saying, "It's okay, let's put this out."
• The whole neighborhood burns down (autoimmunity or rejection).

The Solution: If you take away the matches (IL-17A) or the megaphone (RORγt), those aggressive neighbors suddenly realize, "Oh, we were just yelling at nothing," and they start helping to put out the fire instead of starting it.

Why This Matters

This paper gives us a new "ID badge" (TIM-4) to find these aggressive B cells and a new "off switch" (blocking IL-17A or RORγt). This could lead to new treatments for:

• Autoimmune diseases (like MS or Rheumatoid Arthritis) by calming down the angry B cells.
• Organ Transplants by helping the body accept the new organ instead of rejecting it.
• Cancer (potentially), by understanding how to stop these cells from helping tumors grow.

In short: The immune system has a "bad cop" B cell that we didn't fully understand before. Now that we know how to identify it and how to stop its aggressive shouting, we might be able to fix some of the immune system's worst mistakes.

Technical Summary

1. Problem Statement

While B cells are traditionally known for antibody production, they also function as potent regulators of immune responses. Regulatory B cells (Bregs), often marked by TIM-1, suppress inflammation via cytokines like IL-10. Conversely, effector B cells (Beffs) promote inflammation, autoimmunity, and graft rejection. However, the phenotype and regulatory mechanisms of Beffs remain poorly defined compared to Bregs. Specifically:

• There is no broad, unifying marker for Beffs that express various proinflammatory cytokines.
• The relationship between B cells expressing different inflammatory cytokines (e.g., IFN-$\gamma$, IL-17A) is unclear.
• The role of B cell-derived IL-17A in autoimmunity and transplantation, and its regulation by transcription factors like ROR$\gamma$t, has not been fully elucidated.

2. Methodology

The authors employed a combination of murine models, flow cytometry, genetic manipulation, and high-throughput sequencing:

• Mouse Models: Used C57BL/6 (WT), BALB/c, $\mu$MT (B cell-deficient), Il17a $^{-/-}$, Rorc $^{-/-}$ (ROR$\gamma$t deficient), Il23r $^{-/-}$, and Il17rc B cell-specific knockouts. Inducible B cell-specific Rorc knockout (ROR$\gamma$t-iBKO) mice were generated using hCd20-ERT2.Cre.
• Disease Models:
  • Experimental Autoimmune Encephalomyelitis (EAE): Induced via MOG35-55 immunization to model multiple sclerosis.
  • Allograft Rejection: Islet transplantation (BALB/c to diabetic B6 mice) to study alloimmunity.
• Cell Sorting and Stimulation: Sorted TIM-4$^+$, TIM-1$^+$, and double-negative (DN) B cells. Stimulated with anti-IgM, IL-23, IL-17A, and neutralizing antibodies in vitro.
• Genetic Manipulation: Adoptive transfer of WT vs. Il17a $^{-/-}$ B cells into $\mu$MT mice; generation of bone marrow (BM) chimeras to isolate B cell-intrinsic effects.
• Omics and Molecular Analysis:
  • Flow Cytometry: Intracellular cytokine staining (IL-17A, IL-10, IFN-$\gamma$, GM-CSF, etc.) and surface marker analysis (TIM-1, TIM-4, ROR$\gamma$t).
  • qPCR: Quantification of Il17a and Il10 mRNA.
  • Bulk RNA-seq: Performed on sorted TIM-4$^+$ vs. TIM-1$^+$ B cells (stimulated and unstimulated) to identify transcriptional signatures and compare them to pathogenic Th17 (pTh17) cells.

3. Key Contributions

• Identification of TIM-4 as a Broad Marker for Beffs: The study establishes TIM-4 as a specific marker for a subset of B cells that express ROR$\gamma$t and a proinflammatory cytokine module, distinct from TIM-1$^+$ Bregs.
• Discovery of ROR$\gamma$t in B Cells: This is the first description of ROR$\gamma$t expression in B cells, linking them to the Th17 lineage.
• Autocrine Regulation of Beff Fate: The paper demonstrates that B cell-derived IL-17A acts in an autocrine manner to enforce proinflammatory function and suppress the conversion of Beffs into IL-10-producing regulatory B cells.
• Mechanism of Cytokine Cross-Regulation: The study elucidates how IL-23 and IL-17A signaling pathways differentially regulate IL-10 expression in TIM-4$^+$ (Beff) versus TIM-1$^+$ (Breg) subsets.

4. Key Results

A. Phenotypic Characterization of TIM-4$^+$ B Cells

• Cytokine Profile: TIM-4$^+$ B cells preferentially express IL-17A, IL-22, IL-6, IL-1$\beta$, GM-CSF, and IFN-$\gamma$. They exhibit a high IL-17A:IL-10 ratio compared to TIM-1$^+$ B cells.
• ROR$\gamma$t Dependence: ROR$\gamma$t expression is almost exclusive to TIM-4$^+$ B cells. Deletion of Rorc (encoding ROR$\gamma$t) abolishes IL-17A production in B cells.
• Stimulation: IL-23 signaling is required to induce IL-17A expression in TIM-4$^+$ B cells, acting through ROR$\gamma$t.

B. Functional Impact on Autoimmunity and Transplantation

• EAE Severity: Transfer of Il17a $^{-/-}$ B cells into $\mu$MT mice significantly reduced EAE severity compared to WT B cell transfer.
• Allograft Rejection: Transfer of WT TIM-4$^+$ B cells accelerated islet allograft rejection. Conversely, transfer of Il17a $^{-/-}$ or Rorc $^{-/-}$ TIM-4$^+$ B cells prolonged graft survival.
• Regulatory Shift: B cells lacking IL-17A or ROR$\gamma$t showed a marked increase in IL-10 production (up to 3-fold in TIM-4$^+$ cells), suggesting IL-17A normally suppresses IL-10.

C. Molecular Regulation of IL-17A and IL-10

• Positive Feedback Loop: IL-17A promotes its own expression in TIM-4$^+$ B cells via an autocrine loop. Neutralizing IL-17A reduces Il17a mRNA levels.
• Inhibition of IL-10:
  • IL-17A directly inhibits IL-10 secretion and Il10 mRNA expression in both TIM-4$^+$ and TIM-1$^+$ B cells.
  • IL-23 inhibits IL-10 in TIM-4$^+$ B cells primarily through an IL-17-dependent mechanism (via ROR$\gamma$t).
  • In TIM-1$^+$ B cells, IL-23 inhibits IL-10 via an IL-17-independent pathway.
• ROR$\gamma$t Direct Suppression: ROR$\gamma$t directly binds to Il10 promoter/enhancer elements to suppress IL-10, independent of IL-17.

D. Transcriptomic Analysis (RNA-seq)

• Proinflammatory Module: TIM-4$^+$ B cells upregulate a gene signature resembling pathogenic Th17 (pTh17) cells, including Il17f, Il22, Csf2 (GM-CSF), Il6, Il1b, and chemokines (Ccl3, Ccl4, Ccl5).
• Distinct from pTh17: While sharing cytokine profiles, TIM-4$^+$ B cells lack expression of canonical pTh17 markers like Rbpj and Il23r (though they respond to IL-23), suggesting distinct differentiation pathways.
• Pathway Enrichment: Stimulated TIM-4$^+$ B cells show enrichment in immune activation, stress response, and metabolic reprogramming pathways.

5. Significance

• Redefining B Cell Heterogeneity: The study provides a unified framework for understanding proinflammatory B cells, identifying TIM-4 and ROR$\gamma$t as central regulators of the Beff phenotype.
• Therapeutic Implications:
  • Autoimmunity: Targeting the IL-23/ROR$\gamma$t/IL-17 axis in B cells could mitigate diseases like Multiple Sclerosis (EAE model) by promoting the conversion of pathogenic Beffs into regulatory B cells.
  • Transplantation: Enhancing IL-17 deficiency or blocking IL-17 signaling in B cells could improve allograft survival.
  • Cancer: Conversely, in tumor settings, blocking this pathway might be detrimental if Beffs are required for anti-tumor immunity, highlighting the context-dependent nature of these cells.
• Mechanistic Insight: The discovery of an autocrine IL-17 loop that enforces Beff identity and suppresses Breg function offers a new target for modulating immune tolerance versus inflammation.

In conclusion, this paper establishes TIM-4$^+$ ROR$\gamma$t$^+$ B cells as a distinct, proinflammatory subset that drives autoimmunity and graft rejection, regulated by a self-reinforcing IL-17A loop that prevents their conversion into regulatory cells.